A Phase 0 research study of intravenous Aminolevulinic Acid Hydrochloride (ALA) and MR-guided focused ultrasound device (MRgFUS) in recurrent high-grade glioma patients.Learn More
A Phase 0/2 study of pamiparib (a PARP inhibitor) in newly diagnosed and recurrent glioblastoma patients to evaluate brain penetration and tumor effects.Learn More
A Phase 0 clinical trial combining Abemaciclib (CDK4/6 inhibitor) and LY3214996 (ERK inhibitor) in recurrent glioblastoma patients scheduled for resection to evaluate central nervous system (CNS) penetration.Learn More
A Phase 2 trial that studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to Bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient's response to treatment.Learn More
RIBOCICLIB FOR RECURRENT GLIOBLASTOMA
A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade glioma patients scheduled for resection.
A Phase 0/2 study of ribociclib in combination with everolimus in preoperative Rb-intact recurrent high-grade glioma patients scheduled for resection.Learn More